A phase 2, 12-week randomized, double-blind, placebo-controlled, study to evaluate safety, tolerability, pharmacokinetic and effect on glycemic control of p1736-05 in subjects with type 2 diabetes mellitus

Piramal Enterprises ltd0 个研究点目标入组 130 人开始时间: 待定最近更新: 2021年11月24日

试验速览

阶段: 2 期
状态: 已完成
发起方: Piramal Enterprises ltd
入组人数: 130

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

入选标准

•1.Age : at screening > 35 and < 65 yrs.
•2.BMI : at screening 23 - 40 kg/m2, (weight in Kilogram/(Height in m)2) inclusive.
•3.HbA1c : at screening and pre-randomization between 7.5 and 10%.
•4.Fasting Plasma Glucose (FPG ) : at screening between 130 mg/dl to 250 mg/dl.
•5.Fasting C-peptide: at screening ≥ 0.16nmol/L (> 0.5ng/ml).
•6.For men: Willingness to use adequate contraception from screening until 3 months after the follow-up visit.
•7.For females: negative pregnancy test at screening and or of no childbearing potential (females) (a prerequisite for female subjects of childbearing potential is adequate contraception during the study and until 3 months after the follow-up visit).
•Postmenopausal females: postmenopausal status is usually based on history of amenorrhoea duration (no menstrual period for 24 consecutive months).
•8.Has an established clinical diagnosis of type 2 diabetes mellitus for at least 3 months prior to the screening period; (Type 2 Diabetes Mellitus as defined by the criteria of the American Diabetes Association and recognized by World Health Organization (WHO) Expert Committee on the Diagnosis and Classification of Diabetes Mellitus [American Diabetes Association, 2006]).
•9.Subjects should be Drug naive (Defined as subjects who have not received any pharmacological treatment for at least 12 weeks before screening and no anti-diabetic agents for ≥ 4 consecutive months any time in the past).
•10.Is on a stable weight level, with no more than a 4% gain or loss in the 3 months prior to screening (by history).
•11.Willing to give written informed consent to participate in the study.

排除标准

•1.MODY (Mature Onset Diabetes of the Young), or other unusual or rare forms of diabetes mellitus, type I diabetes mellitus.
•2.Type 2 Diabetes of more than 8 years duration prior to screening.
•3.Has a history of acute diabetic complications such as ketoacidosis or hyperosmolar nonketotic coma within 6 months prior to screening.
•4.Has a history of insulin use within 6 months prior to screening.
•5.Has used oral anti-diabetic medications within 3 months prior to screening.
•6.Has received any investigational drug within 60 days prior to screening.
•7.Has a history of hypersensitivity or allergies to similar class of drug as the study drug, unless approved by the Investigator.
•8.Has a clinically significant history of substance or alcohol abuse within the past year or a current diagnosis of substance or alcohol abuse.
•9.Has a positive serology for Hepatitis B or C at screening or known history of HIV at screening.
•10.Has donated blood (>=500mL) within the 3 months preceding the screening period or suffered significant blood loss equal to a donor portion (approx 500mL).
•11.Has history of clinically significant disease other than type 2 diabetes (endocrine, hepatic, renal, metabolic, neurological, psychiatric, cardiovascular, pulmonary, gastrointestinal, hematological or gynecological disease (including subjects with diabetic end organ disease (renal, cardiac, and retinal)
•oSubjects with significant renal insufficiency, only one functioning kidney, history of renal transplantation, or currently receiving renal dialysis.
•oSubjects with serum creatinine >=1.5 mg/dL or >=132.6 Âµmol/L
•oSubjects with a clinically significant abnormal WBC count, thrombocytopenia, or anemia at screening.
•oSubjects with history or presence of proliferate retinopathy, macular degeneration or edema, retinal detachment, and/or severe vision impairment (i.e. subject requires assistance in daily tasks).
•oSubjects with hepatic disease or clinically relevant evidence of it (i.e. values at screening or pre randomization of more than 3 x ULN for aspartate aminotransferase [AST], alanine aminotransferase [ALT] or alkaline phosphatase or values of more than 1.5 x ULN for bilirubin). Subjects with high bilirubin associated with Gilberts syndrome will not be excluded.
•oSubjects who have a history of malignancy.
•oSubjects with cardiovascular disease within the previous 6 months prior to screening (including, but not limited to, myocardial infarction, stroke, peripheral vascular disease, ischemic changes at resting ECG).
•oSubjects with severe and uncontrolled hypertension (blood pressure above 160/100 mmHg).
•oSubjects with a history of unhealed diabetic ulcer.
•oSubjects with hypo or hyperthyroidism.
•12.Subjects who have been hospitalized for any psychiatric illness in the past year, or are diagnosed with major depression.
•13.Subjects with any other clinically significant laboratory abnormality at screening.
•14.Has a clinical condition or receiving therapy that, in the opinion of the Investigator, would make the subjects unsuitable for study.
•15.Subjects who have received in the 3 months prior to screening, any systemic glucocorticoid treatment.
•16.Use of antiobesity treatments within 3 months prior to screening.

研究者

发起方

Piramal Enterprises ltd

相似试验

进行中（未招募）

1 期

A 24-week phase 2, double-blind, placebo-controlled, single-centre safety and efficacy study to evaluate overall safety and tolerability of co-administration of tesofensine and metoprolol in subjects with obesity caused by an injury in hypothalamus (HIO), and with a 24-week open-label extension, in total 48 weeks

EUCTR2018-003672-12-DKSaniona A/S25

尚未招募

2 期

A phase 2, 12-week, randomized, double-blind, placebo-controlled study of DS-1211b in individuals with pseudoxanthoma elasticumpseudoxanthoma elasticum

NL-OMON51483Daiichi Sankyo, Inc16

进行中（未招募）

1 期

Investigation to Efficacy and Safety of CC-90001 in patients with Idiopathic Pulmonary FibrosisMedDRA version: 20.0Level: LLTClassification code 10067761Term: Exacerbation of idiopathic pulmonary fibrosisSystem Organ Class: 100000004855IDIOPATHIC PULMONARY FIBROSIS

EUCTR2016-003473-17-GRCelgene Corporation135

进行中（未招募）

1 期

EUCTR2016-003473-17-GBCelgene Corporation135

进行中（未招募）

不适用

An study conducted in multiple countres to assess the control of glucose in patients with Diabetes Type 2. This study will compare 5 different dose levels of HM11260C (the study medication) with placebo (no active drug) and a liraglutide (a treatment for diabetes type 2 available by prescription). This will be a twelve week study where the study physician nor the patient will know whether the treatment is placebo or study medication. There is an equal chance of being assigned to any group.Type 2 Diabetes Mellitus

EUCTR2013-003625-29-HUHanmi Pharmaceutical Co., Ltd.255